via University of Southampton
Scientists from the Antibody and Vaccine group at the University of Southampton have discovered a way to transform antibody drugs previously developed to treat autoimmunity into antibodies with powerful anti-cancer activity through a simple molecular “switch”.
This work, published in the journal Cancer Cell, focuses on a molecule called CD40 which is present on the surface of immune cells and controls both autoimmunity and cancer. In autoimmunity, CD40 is thought to be over-stimulated, increasing the chance of the immune system attacking healthy tissues; whereas in cancer, CD40 is believed to be under-stimulated, enabling tumour cells to evade the immune system. Targeting of CD40 with antibody drugs is ongoing in therapeutic interventions for both diseases.
Accordingly, antibody drugs have been developed to either activate (agonists) or suppress (antagonists) the CD40 immune pathway. Researchers at the Centre for Cancer Immunology in Southampton, led by Professors Mark Cragg and Martin Glennie now reveal that an antagonist CD40 antibody can be transformed into an agonist by simply modifying the “constant” domain of the antibody. The antagonist-turned agonist “trick” was shown for three different antagonists, being driven by the hinge part of the constant domain that controls the flexibility of the antibody. One of these antibodies, was shown to be a “super”-agonist that could stimulate the immune system and cure cancer more effectively in preclinical models than the best CD40-targeting antibody currently in clinical trial.
“Being able to toggle between an autoimmune drug and a cancer medicine with a simple switch is really exciting.” said Dr Xiaojie Yu, first author of the study. “We gained a deeper understanding of the mechanism through which CD40 becomes activated, and eagerly look forward to applying this technology to more drug candidates.”
“Our findings build on a history of CD40 research here in Southampton and were surprising and exciting in equal measure,” said Professor Mark Cragg, senior author of the study. “Taking an antibody that suppresses the immune system and turning it on its head, to activate the immune system for cancer through a relatively simple process is unprecedented. More than that, the same approach could be used for other immune targets and we look forward to seeing testing this in the near future”.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- TTUHSC doctor repurposing antipsychotic drug to treat cancer
Treating cancer, by using an existing drug. That’s what a doctor and his team at the Texas Tech University Health Sciences Center Jerry H. Hodge School of ...
- ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma
Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug ...
- Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade
Rather than kill cancer cells like most therapies, PRP induces cancer cells to differentiate so they are no longer malignant and die off naturally ...
- Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11's Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study
PM ET today at the Cytokine Based Drug Development Summit TORONTO and HOUSTON, (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a ...
- Local delivery of anti-CTLA-4 cancer immunotherapy drug is safer than systemic delivery
Results from a clinical trial suggest that local delivery of anti-CTLA-4 immunotherapy drug is safer than systematic delivery.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company
Common stock of Apexigen to commence trading on the Nasdaq Capital Market today under the ticker symbol “APGN”--Clinical pipeline includes multiple Phase 2 studies of sotigal ...
- Flooding in Kentucky; Celtics legend Russell dies; Nichols who played Uhura on 'Star Trek' dies | Hot off the Wire podcast
Former Philippine President Fidel Valdez Ramos, a U.S.-trained ex-general who saw action in the Korean and Vietnam wars and played a key role in a 1986 pro-democracy uprising that ousted a dictator, ...
- Last patient completed follow-up period in Phase II/III study of Amphera’s MesoPher cell therapy in mesothelioma
Amphera B.V., a late-stage biotechnology company developing cell therapies to treat cancer, announces that the last patient has completed the active follow-up in the Phase II/III DENIM study of ...
- Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain
New patent expected to expire in 2036 Phase 2 Study for Prevention of Migraine Headache Expected to Start Second Half 2022 CHATHAM, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals ...
- Nisa Investment Advisors LLC Cuts Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Nisa Investment Advisors LLC lowered its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Rating) by 37.2% during the first quarter, according to the company in its most recent filing with ...